Table 1.
High and intermediate risk regimens for lung and breast cancer patients; the numbers correspond to the dosages per square meter of the substances. AUC = area under the curve for dosing of carboplatin according the Calvert formula. Data originates from the original publications and is mainly published by the German database for oncological treatment protocols Onkopti®, www.onkopti.de; dd = dose dense
| Chemotherapy protocols with a high FN risk (> 20%) | Chemotherapy protocols with an intermediate FN risk (10–20%) |
|---|---|
| Lung cancer (NSCLC) | |
| Gemcitabine 1000/carboplatin 5 AUC | Carboplatin 5 AUC/etoposide 100 |
| Vinorelbine 30/cisplatin 100 (palliative) | Vinorelbine 30/cisplatin 80 |
| Gemcitabine 1250/carboplatin 5 AUC | Vinorelbine 25/cisplatin 100 |
| Gemcitabine 1200/carboplatin 5 AUC | Paclitaxel 200/carboplatin 6 AUC (with bevacizumab) |
| Paclitaxel 200/carboplatin 6 AUC (consolidation after radiotherapy) | |
| Docetaxel 75 (mono) | |
| Vinorelbine 30/cisplatin 100 (adjuvant) | |
| Docetaxel 75 (with nintedanib) | |
| Vinorelbine 30/gemcitabine 1200 (d1.8 q3w) | |
| Vinorelbine 25/carboplatin 5 | |
| Docetaxel 75/cisplatin 75 | |
| Docetaxel 75/carboplatin 6 AUC | |
| Cisplatin 100/etoposide 100 | |
| Docetaxel 85/gemcitabine 1000 | |
| Lung cancer (SCLC) | |
| Topotecan 1.5 (d1–5) | Carboplatin 5 AUC/etoposide 100 |
| Carboplatin 5 AUC/etoposide 140 | Cisplatin 75/etoposide 100 |
| Cisplatin 100/etoposide 100 | Carboplatin 5 AUC/etoposide 120 (q3w) |
| Doxorubicin 60/cyclophosphamide 750/vincristine 1.5 (ACO II) | Cisplatin 80/etoposide 120 (q4w) |
| Epirubicin 40/cyclophosphamide 750/vincristine 1.5 (EPICO) | Cisplatin 80/etoposide 100 |
| Cisplatin 25 (d1–3)/etoposide 80 (d1–3) | Cisplatin 90/etoposide 150 |
| Etoposide 50 d1–21 (q4w) | Cisplatin 80/etoposide 120 (q3w) |
| Carboplatin 6 AUC/etoposide 120 (q4w) | |
| Carboplatin 300/etoposide 100 | |
| Cisplatin 60/etoposide 120 | |
| Cyclophosphamide 1000/doxorubicin 50/Vincristine 1,4 (CAV) | |
| Carboplatin 5 AUC/etoposide 80 | |
| Cisplatin 80/etoposide 150 | |
| Carboplatin 300 (d1)/etoposide 140 (d1–3)/vincristine 1.4 (d1.8.15) | |
| Topotecan 1.5/cisplatin 75 | |
| Topotecan 2.3 | |
| Topotecan 1.5 (d1–4) | |
| Topotecan 0.75 (d1–5)/carboplatin 5 AUC | |
| Irinotecan 60/cisplatin 60 | |
| Cisplatin 20/etoposide 75/ifosfamide 1,2 (d1–4 q3w) | |
| Cisplatin 80/etoposide 80 | |
| Breast cancer | |
| Docetaxel 75/doxorubicin 50/cyclophosphamide (TAC) 500 | Epirubicin 90/cyclophosphamide 600 (q3w) |
| Epirubicin 150 → paclitaxel 225 → cyclophosphamide 2500 (ETC) (dd) | Epirubicin 75/cyclophosphamide 600 (q3w) |
| dd Epirubicin 90/cyclophosphamide 600 → paclitaxel 175 (q2w) | Doxorubicin 75/cyclophosphamide 600 (q3w) |
| Docetaxel 75/carboplatin 6 AUC (TCH) | Vinorelbine 30 (with trastuzumab)(d1,8 q3w) |
| dd Epirubicin 150 → nab-paclitaxel 330 → cyclophosphamide 200 (GAIN-2 study) | Docetaxel 100 (with trastuzumab, pertuzumab) Eribulin 1.23 d1.8 |
| dd Epirubicin 90/cyclophosphamide 600 → docetaxel 60 (EC-part) (q2w) | Docetaxel 75 (with trastuzumab, pertuzumab) |
| Epirubicin 150 → paclitaxel 225 → cyclophosphamide 2000 (q2w) (GeparOcto study) Paclitaxel 175 (mono) (q2w) Doxorubicin 60/cyclophosphamide 600 → -paclitaxel 175 (q2w) (AC-part) Docetaxel 75/cyclophosphamide 600 dd Epirubicin 90/cyclophosphamide 600 → docetaxel 75 (q2w) (Doce-Part) |
Doxorubicin 60/cyclophosphamide 600 → paclitaxel 80 weekly (AC-part) (q3w) 5-Fluoruracil 500/epirubicin 90/cyclophosphamide 600 (FEC) → docetaxel 100 (Doce-part) Epirubicin 90/cyclophosphamide 600 → docetaxel 60 (Doce-part) (q3w) Gemcitabine 1000/carboplatin 4 AUC Docetaxel 75/gemcitabine 1000 Doxorubicin (lip.) 75/cyclophosphamide 600 Paclitaxel 175 (mono) (q3w) |
| Doxorubicin 75/cyclophosphamide 600 | Paclitaxel 175 (mono) (q4w) |
| Docetaxel 100 (with trastuzumab) | Gemcitabine 1000/cisplatin 50 d1.14 |
| Doxorubicin 60 → paclitaxel 175 → cyclophosphamide 600 (A → P→ C) (q2w) | |
| Epirubicin 75/cyclophosphamide 600 (q2w) | |
| Doxorubicin 60/cyclophosphamide 600 → paclitaxel 175 (q2w) (Pac-part) | |
| Doxorubicin 50/docetaxel 75 | |